![Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/0ae1a419-8c04-4e6e-8a98-2b83b3eaa1d8/gr1.gif)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology
![Immunotherapy vs. Ewing Sarcoma: LET'S GO! — Little Warrior Foundation | Find the Cure for Childhood Cancer Immunotherapy vs. Ewing Sarcoma: LET'S GO! — Little Warrior Foundation | Find the Cure for Childhood Cancer](http://static1.squarespace.com/static/5de28c8008114a27bbd10042/5f48257d18e160050b29d7e5/61ba7bc5dc340c374dc4e6df/1639674937976/851CBEAB-1913-4CC8-863C-BF92717C2FAD.jpeg?format=1500w)
Immunotherapy vs. Ewing Sarcoma: LET'S GO! — Little Warrior Foundation | Find the Cure for Childhood Cancer
![Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma](https://www.frontiersin.org/files/MyHome%20Article%20Library/454940/454940_Thumb_400.jpg)
Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization | ACS Biomaterials Science & Engineering
![Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-019-0756-z/MediaObjects/13045_2019_756_Fig1_HTML.png)
Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text
![Is immunotherapy in the future of therapeutic management of sarcomas? | Journal of Translational Medicine | Full Text Is immunotherapy in the future of therapeutic management of sarcomas? | Journal of Translational Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12967-021-02829-y/MediaObjects/12967_2021_2829_Fig3_HTML.png)